E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1.To determine the effect of four different doses of DG-031 on serum CRP levels (250mg t.i.d., 500mg b.i.d., 375mg t.i.d. and 500mg t.i.d.).
|
|
E.2.2 | Secondary objectives of the trial |
1.To determine the effect of four different doses of DG-031 on plasma LTB4 and MPO levels. 2.To assess the tolerability and safety of DG-031, 250 mg t.i.d., 375 mg t.i.d., 500 mg b.i.d. and 500mg t.i.d. in patients with CAD and history of MI.
Exploratory objectives:
1. To determine the effect of four different doses of DG-031 on other biomarkers of MI risk, including but not limited to CD40L and PGF. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Age 40 to 75. 2. Serum CRP levels of ≥2.0. 3. Diagnosis of CAD (based on interview, medication history and physical examination) and history of MI. 4. Postmenopausal women or women of childbearing potential willing to use two adequate barrier methods of contraception or willing to abstain from heterosexual activity throughout the study, starting with Visit 1 and for 14 days after the last dose of study medication. Refer to section 13.5.2 for information on adequate contraceptive methods. All women of childbearing potential must have a negative urine pregnancy test at Visit 1. Note: Women of childbearing potential are defined as premenopausal, not having had surgical sterilisation (hysterectomy or bilateral tubal ligation or bilateral oophorectomy). Postmenopausal status is defined as ≥45 years of age with >2 years since last menses. 5. Understanding of the study procedures and agreement to participate in the study by giving written informed consent.
|
|
E.4 | Principal exclusion criteria |
1. Congestive heart failure (CHF). 2. Any experimental treatment within 2 months of screening or planned for the following 2 months. 3. Acute CV event (such as ACS, MI or stroke) within 1 month prior to enrolment. 4. Elevated CPK above 3 fold upper normal limit (UNL). Other liver function tests and kidney function tests above 1.5 fold upper normal limit. 5. Immunocompromised subjects, including subjects known to be HIV positive or with malignant disease and/or on chronic immunosuppressive therapy. 6. Subjects known to have positive serology results for HBsAg, HCV Ab. 7. Treatment with immunosuppressive cytotoxic drugs or corticosteroids within 6 weeks or during conduct of study. 8. Major surgery within 6 weeks prior to enrolment. 9. Any other major intercurrent illness and other condition, which, in the investigator’s judgement, will interfere with the subject’s participation in this study. 10. Subjects not willing to return for follow-up or with known history of non-compliance. 11. Subjects not willing to adhere to restrictions of alcohol use for the duration of the study (≤3 units of alcohol/day or ≤15 units of alcohol/week and no alcohol for 48 hours prior to clinic visits). Note: A unit of alcohol is defined as a single measure of spirit (25 ml), one small glass of sherry or fortified spirit (50 ml), one small glass of wine (125 ml) or one small regular strength beer (330 ml, 4-5%). 12. Pregnant or lactating women. 13. Poor mental function or any other reason to expect difficulty in complying with the requirements of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Changes in serum levels of CRP. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |